Peptide · Fact sheet
MOTS-c
Also known as MOTS-c peptide · mitochondrial ORF of 12S rRNA type-c
MOTS-c is an experimental mitochondrial-derived peptide studied for metabolism, exercise adaptation, and aging biology. It is not FDA approved, and FDA reports no identified human exposure data for drug products containing MOTS-c.
What is MOTS-c?
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA and produced as part of cellular stress and metabolic signaling.
Studies measuring natural MOTS-c levels in people are not treatment trials, and a synthetic analog such as CB4211 is not interchangeable with native MOTS-c.
Benefits people look for
Animal studies report effects on insulin sensitivity, metabolic stress, physical capacity, and age-related decline.
Those findings have fueled 'exercise mimetic' and longevity claims that go far beyond direct human intervention evidence.
What the evidence supports
- Animal studies report improved insulin sensitivity and physical capacity under selected experimental conditions.
- Human observational work shows associations with exercise and muscle measures, but association does not prove that administering MOTS-c produces a benefit.
All research areas
- Insulin sensitivity and metabolic regulation in animal models
- Exercise adaptation and physical capacity
- Age-related metabolic decline
- Muscle stress and mitochondrial signaling
- Metabolic disease and fatty-liver research
- Exercise and muscle-function biology
- Healthy-aging mechanisms
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- FDA identifies potential immune reactions and complexities involving peptide impurities and active-ingredient characterization.
- There is no adequate human treatment dataset from which to estimate common, uncommon, or long-term harms.
- Unapproved products add identity, purity, sterility, strength, and labeling risks.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Mostly animal or lab researchMost treatment claims come from cells and animals. Human studies largely measure naturally circulating MOTS-c or response to exercise rather than test MOTS-c as a therapy.
Selected research to read
Preclinical study in animal models; it does not establish a human treatment effect.
Study of naturally circulating peptide levels after exercise, not administration as a therapy.
Completed early trial of a MOTS-c analog; the registry does not show public results and the analog is not native MOTS-c.
FDA approval & research status
No MOTS-c drug product is FDA approved. FDA's current compounding safety summary states that it has not identified human exposure data for drug products containing MOTS-c.
No FDA-approved use is documented in the records summarized on this page.
Native MOTS-c remains preclinical as a treatment
Most treatment claims rely on animal or laboratory work. A related CB4211 analog reached Phase 1, but that analog is not interchangeable with native MOTS-c.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Whether administered MOTS-c produces any meaningful human metabolic or performance benefit
- Short- and long-term human safety
- How synthetic products compare with the naturally produced peptide
- Whether animal longevity or exercise findings translate to people
The takeaway
MOTS-c is compelling mitochondrial biology, not a proven exercise or longevity treatment. The missing step is direct, controlled human evidence with a characterized product.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA: safety risks for selected compounded bulk substances
FDA's current substance-specific summary of evidence gaps and potential safety risks.
- 2pubmedMOTS-c metabolism and insulin-sensitivity study
Preclinical study in animal models; it does not establish a human treatment effect.
- 3pubmedHuman exercise study of mitochondrial-derived peptides
Study of naturally circulating peptide levels after exercise, not administration as a therapy.
- 4clinical trialsClinicalTrials.gov: CB4211 Phase 1 study
Completed early trial of a MOTS-c analog; the registry does not show public results and the analog is not native MOTS-c.